<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03071133</url>
  </required_header>
  <id_info>
    <org_study_id>AI443-144</org_study_id>
    <nct_id>NCT03071133</nct_id>
  </id_info>
  <brief_title>Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy</brief_title>
  <official_title>Asunaprevir/Daclatasvir/Beclabuvir Fixed-Dose Combination Safety Surveillance in Japanese Patients With Chronic Hepatitis C (HCV) or Japanese Patients With Compensated Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An observational, postmarketing commitment following the marketing authorization for DCV Trio
      therapy in Japan
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2017</start_date>
  <completion_date type="Anticipated">November 20, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 20, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Aspartate Aminotransferase (AST) elevation</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>measured by immunoassay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Alanine Aminotransferase (ALT) elevation</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>measured by immunoassay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Total Bilirubin (tBili) elevation</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>measured by immunoassay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse drug reactions (ADRs) in HCV patients treated with DCV Trio therapy in Japan</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>measured by adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with undetectable HCV RNA at 12 weeks post-treatment (SVR12)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>measured by number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with undetectable HCV RNA at 24 weeks post-treatment (SVR24)</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>measured by number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients to experience virologic breakthrough</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>measured by percentage of patients</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Hepatitis C</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in Japan who are initiating treatment with DCV Trio therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are initiating the treatment with DCV Trio therapy under the approved
             indications, dosage, and administration

        Exclusion Criteria:

          -  Patients who use the DCV Trio off label
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tokyo</city>
        <zip>1620814</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2017</study_first_submitted>
  <study_first_submitted_qc>March 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2017</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

